Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,167
datasets available to search
ShareScore release 0.9.0
Dataset results
1,167 results for “Real-world”
Chinese Real-world Study of Treatment of Vestibular Migraine
ClinicalTrials.gov study NCT07203248. IPD Sharing: NO. Countries: 0. Publications: 0.
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
ClinicalTrials.gov study NCT05984615. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients
ClinicalTrials.gov study NCT05332470. IPD Sharing: NO. Countries: 0. Publications: 0.
A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
ClinicalTrials.gov study NCT06963632. IPD Sharing: NO. Countries: 0. Publications: 0.
VISSIM and real-world eco-approach and departure comparison
Open the record for dataset details and reuse information.
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma [RNA-seq]
GEO Series GSE298011. Homo sapiens. 3 samples. Type: Expression profiling by high throughput sequencing.
Key Real-World Applications of Classifier Ensembles
Broad classes of statistical classification algorithms have beendeveloped and applied successfully to a wide range of real worlddomains. In general, ensuring that the particular classificationalgorithm matches the properties of the data is crucial inproviding results that meet the needs of the particular applicationdomain. One way in which the impact of this algorithm/applicationmatch can be alleviated is by using ensembles of classifiers, wherea variety of classifiers (either different types of classifiers ordifferent instantiations of the same classifier) are pooled before afinal classification decision is made. Intuitively, classifierensembles allow the different needs of a difficult problem to behandled by classifiers suited to those particular needs.Mathematically, classifier ensembles provide an extra degree offreedom in the classical bias/variance tradeoff, allowing solutionsthat would be difficult (if not impossible) to reach with only asingle classifier. Because of these advantages, classifier ensembles have been applied to many difficult real world problems. In this paper, we surveyselect applications of ensemble methods to problems that havehistorically been most representative of the difficulties inclassification. In particular, we survey applications of ensemblemethods to remote sensing, person recognition, one vs. allrecognition, and medicine.
Addressing the Real-World Challenges in the Development of Propulsion IVHM Technology Experiment (PITEX)
The Propulsion IVHM Technology Experiment (PITEX) has been an on-going research effort conducted over several years. PITEX has developed and applied a model-based diagnostic system for the main propulsion system of the X-34 reusable launch vehicle, a space-launch technology demonstrator. The application was simulation-based using detailed models of the propulsion subsystem to generate nominal and failure scenarios during captive carry, which is the most safety-critical portion of the X-34 flight. Since no system-level testing of the X-34 Main Propulsion System (MPS) was performed, these simulated data were used to verify and validate the software system. Advanced diagnostic and signal processing algorithms were developed and tested in real-time on flight-like hardware. In an attempt to expose potential performance problems, these PITEX algorithms were subject to numerous real-world effects in the simulated data including noise, sensor resolution, command/valve talkback information, and nominal build variations. The current research has demonstrated the potential benefits of model-based diagnostics, defined the performance metrics required to evaluate the diagnostic system, and studied the impact of real-world challenges encountered when monitoring propulsion subsystems.
G-REx: A Real-World Dataset of Group Emotion Experiences based on Physiological Data
<p>G-REx is a dataset for real-world affective computing. We collected physiological data (photoplethysmography and electrodermal activity) using a wrist-worn device during long-duration movie sessions. Emotion annotations were retrospectively performed on segments with elevated physiological responses. The dataset includes over 31 movie sessions, totaling 380 h+ of data from 190+ subjects. The data were collected in a group setting, which can give further context to emotion recognition systems.</p> <p> </p> <p><strong>TO HAVE ACCESS PLEASE FILL OUT: <a href="https://forms.gle/nhBRW2S2JrE5QB878" target="_blank" rel="noopener">https://forms.gle/nhBRW2S2JrE5QB878</a></strong></p>
LLAMAFUZZ real-world programs supplementary experiment data
<div> <p>This is the raw experimental data of LLAMAFUZZ and AFL++ on a set of real-world programs. We choose FuzzBench as running framework to ensure the fairness.</p> </div>
Exhaust emissions from a gasoline vehicle under real-world driving conditions
<p>Exhaust emissions from a gasoline vehicle under real-world driving conditions</p>
Dataset related to the article "Sex effect on efficacy of pulmonary vein cryoablation in patients with atrial fibrillation: data from the multicenter real-world 1STOP project"
<p>This record contains raw data related to the article "Sex effect on efficacy of pulmonary vein cryoablation in patients with atrial fibrillation: data from the multicenter real-world 1STOP project”</p> <p> </p> <p>ABSTRACT</p> <p>PURPOSE:</p> <p>Pulmonary vein isolation (PVI) using cryoablation (PVI-C) is a widespread therapy for treating symptomatic, recurrent atrial fibrillation (AF). The impacts of sex on efficacy and safety of PVI-C in a real-world clinical practice is lacking. In a multicenter prospective project, we evaluated whether clinical characteristics, procedure parameters, procedural complications, long-term AF recurrence rates, and/or AF-related symptoms differed according to sex in patients treated with PVI-C.</p> <p>METHODS:</p> <p>Data from the study population were collected in the framework of the 1STOP ClinicalService® project, involving 47 Italian cardiology centers. Multivariable statistical analyses were conducted to determine if any baseline clinical characteristics impacted the efficacy of PVI-C.</p> <p>RESULTS:</p> <p>From April 2012, 2125 patients (27% female, 59 ± 11 years, 73% paroxysmal AF, and mean left atrial diameter = 42 ± 8 mm) underwent PVI-C. According to baseline characteristics, women were more likely to be older, with higher clinical risk scores (e.g., CHA<sub>2</sub>DS<sub>2</sub>-VASc), and a higher number of tested antiarrhythmic drugs before the index PVI-C procedure. Male and female cohorts showed comparable procedure time (mean =&thinsp;107.7 ± 46.8 min) and a similar incidence of periprocedural complications (4.5% overall), even after adjustment for baseline characteristics (P =&thinsp;0.880). The multivariable analyses demonstrated that the strongest predictor of AF recurrences was sex (0.74; 95% CI 0.58-0.93; P =&thinsp;0.011). After propensity score adjustment, the hazard ratio from a multivariable model, which included age and AF type (persistent) as covariates, was 0.76 (0.60-0.97) (P =&thinsp;0.025).</p> <p>CONCLUSIONS:</p> <p>According to the 1STOP project, in a real-world setting, PVI-C was relatively safe regardless of the patient's sex; however, when considering efficacy of the procedure, female patients had a lower long-term efficacy in comparison to males.</p> <p>CLINICAL TRIAL REGISTRATION: <a href="http://clinicaltrials.gov/show/NCT01007474">NCT01007474</a>.</p> <p> </p> <p> </p> <p> </p>
Dataset related to the article "A comparison of acute procedural outcomes within four generations of cryoballoon catheters utilized in the real-world multicenter experience of 1STOP"
<p>This record contains raw data related to the article “A comparison of acute procedural outcomes within four generations of cryoballoon catheters utilized in the real-world multicenter experience of 1STOP".</p> <p> </p> <p><strong>Abstract</strong></p> <p><strong>Introduction: </strong>Four generations of the cryoballoon (CB) catheter were retrospectively evaluated in a real-world examination of patients with atrial fibrillation (AF).</p> <p><strong>Methods and results: </strong>Four hundred eighty patients (27% female and 60 ± 10 years) suffering from AF, underwent pulmonary vein (PV) ablation with one-of-four generations of the CB catheter. The total cohort was divided into four groups of patients: 120 with first-generation (CB-1); 120 with second-generation (CB-2); 120 with third-generation (CB-3); and 120 with fourth-generation (CB-4). Equal group sizes were achieved by examining the last 120 patients treated in each cohort, attempting to minimize the effect of a learning curve between the generations of CB catheter. Baseline clinical and patient characteristics were similar between the four cohorts, excepting age and the number of tested antiarrhythmic drugs. Procedure, fluoroscopy, and left atrial dwell times were significantly lower in the CB-4 cohort compared to previous generations of the CB catheters, while the acute procedural success rate was comparable across all catheter groups (>99%). Total acute procedural complications were low (2.5%), and acute complications were comparable within the CB-2, CB-3, and CB-4 groups (0.8% reported in each cohort). The rate of time-to-isolation (TTI) visualization increased with later generations of the CB catheters.</p> <p><strong>Conclusions: </strong>The novel CB-4 achieved significantly faster procedural ablation times in comparison to the previous generations, while still maintaining a low rate of acute complications. Also, the rate of TTI visualization was observed to be higher with the CB-4 catheter. Further long-term evaluation is necessary, including an assessment of AF recurrence and PV reconnection(s).</p>
Dataset for the statistical analysis of the paper BONE DAMAGE AFTER CHEMOTHERAPY FOR LYMPHOMA: A REAL-WORLD EXPERIENCE
<p>Dataset used for the statistical analysis of the data to be published in a paper entitled "BONE DAMAGE AFTER CHEMOTHERAPY FOR LYMPHOMA: A REAL-WORLD EXPERIENCE"</p>
Dataset related to article "Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis"
<p>This record contains raw data related to article "Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis"</p><p>Abstract</p><p>Background: The impact of a multidisciplinary management of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis on systemic glucocorticoids or innovative treatments remains unknown. Rule-based natural language processing and text extraction help to manage large datasets of unstructured information and provide insights into the profile of treatment choices.</p><p>Methods: We obtained structured information from text data of outpatient visits between 2017 and 2022 using regular expressions (RegEx) to define elastic search patterns and to consider only affirmative citation of diseases or prescribed therapy by detecting negations. Care processes were described by binary flags which express the presence of RA, PsA and psoriasis and the prescription of glucocorticoids and biologics or small molecules in each cases. Logistic regression analyses were used to train the classifier to predict outcomes using the number of visits and the other specialist visits as the main variables.</p><p>Results: We identified 1743 patients with RA, 1359 with PsA and 2,287 with psoriasis, accounting for 5,677, 4,468 and 7,770 outpatient visits, respectively. Among these, 25% of RA, 32% of PsA and 25% of psoriasis cases received biologics or small molecules, while 49% of RA, 28% of PsA, and 40% of psoriasis cases received glucocorticoids. Patients evaluated also by other specialists were treated more frequently with glucocorticoids (70% vs. 49% for RA, 60% vs. 28% for PsA, 51% vs. 40% for psoriasis; p < 0.001) as well as with biologics/small molecules (49% vs. 25% for RA, 64% vs. 32% in PsA; 51% vs. 25% for psoriasis; p < 0.001) compared to cases seen only by the main specialist.</p><p>Conclusion: Patients with RA, PsA, or psoriasis undergoing multiple evaluations are more likely to receive innovative treatments or glucocorticoids, possibly reflecting more complex cases.</p><p> </p>
Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a ''real-world'' chart review study
<p>Adjunctive vortioxetine for SSRI-resistant major<br> depressive disorder: a ‘‘real-world’’ chart review study</p> <p>Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major<br> depressive disorder (MDD). However, non-response is common, often necessitating combination<br> strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients<br> with SSRI-resistant MDD.<br> Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response<br> after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated<br> with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures<br> were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of<br> response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression - Improvement<br> module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores p 7 were considered as remission.<br> Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale<br> for Suicide Ideation (SSI).<br> Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D<br> score was observed (p p 0.001), with response obtained by 41.7% and remission by 33.3% of<br> patients. Significant reductions in SHAPS and SSI were also observed (p p 0.001 for both scales).<br> Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant<br> depression. However, the limitations of this study (such as small sample size, absence of<br> randomization and control group, retrospective design, etc.) must be considered.</p>
Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting
<p>Psychopharmacological treatment in borderline personality disorder: A<br> pilot observational study in a real-world setting</p> <p>Psychotherapy is the cornerstone of treatment for borderline personality disorder (BPD) while pharmacotherapy<br> should be considered only as an adjunctive intervention. In clinical practice, however, most of BPD patients only<br> receive medication. The aim of the study is to first describe pharmacological treatment in BPD patients in Italy<br> and secondly to evaluate if comorbidity or illness severity are associated with the prescription of different class<br> compounds.<br> Data on pharmacological treatment and clinical evaluation of 75 BPD patients were collected in 5 clinical<br> settings. The association between comorbidity and medication was assessed. Moreover, we evaluated the association<br> between pharmacotherapy and severity, defined by a cluster analysis aimed at detecting different groups<br> of patients.<br> Most of the participants (82.7%) were characterized by polypharmacy, with a mean of 2.4 medications per<br> person. Interestingly, the prescription didn’t seem to depend on/be based on the severity of the disorder and was<br> only partially determined by the presence of comorbidity.<br> In conclusion, our findings are similar to what described in other clinical studies, supporting the idea that<br> medication management for BPD is only partially coherent with international guidelines. This pilot study confirms<br> the need for more rigorous studies to gain greater understanding of this topic and diminish the gap between<br> guidelines and the real clinical world.</p>
Disability and mortality in a cohort of MS patients: how the real-world scenario is changed
<p>Demographical (sex and age) and clinical findings (functional system involved at MS onset, MS type, MS disability evaluated via EDSS scale, time to MS progression and use of disease modifying treatment) collected in a cohort of 86 patients with MS and with first hospitalization at IRCCS Mondino, Pavia (italy) in 2005-2006 and followed until 2018. </p>
Dataset related to the article "Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation in relation to the Patients' Age: Results from a Large Real-World Multicenter Observational Project"
<p>This record contains raw data related to the article "Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation in relation to the Patients' Age: Results from a Large Real-World Multicenter Observational Project"</p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background: </strong>The real-world efficacy and safety of atrial fibrillation (AF) ablation in particularly young and elderly patients are still under debate. The aim of the analysis was to investigate the effect of age on the efficacy and safety of cryoballoon ablation (CBA).</p> <p><strong>Methods: </strong>2,534 patients underwent pulmonary vein isolation (PVI) by way of CBA for paroxysmal or persistent drug-resistant and symptomatic AF. The population was divided into age quartiles for evaluation, including (1) <53 years, (2) ≥53 and <61 years, (3) ≥61 and <67 years, and (4) ≥67 years. Furthermore, outcomes were analyzed in patients <41 years, ≥41 and ≤74, and >74 years old. Procedural data and complications were collected, and atrial fibrillation recurrences were evaluated during follow-up.</p> <p><strong>Results: </strong>Procedural-related complications (4.1%) were similar in the four subgroups according to age. At the 12-month follow-up, freedom from AF recurrence was 79.2%, 77.4%, 76.8%, and 75.2% (<em>p</em>=0.21), respectively (with increasing age). At 24-month follow-up, similar incidences of AF recurrence were observed in the four subgroups. When the sample was arbitrarily divided into the three age groups, a higher rate of recurrence was observed in older patients with regard to long-term follow-up (freedom from AF recurrence was 71.8% and 40.9%, respectively, at 12 and 24-month follow-up). In the univariate and multivariate analysis, age did not result in a significant predictor of AF recurrence during follow-up; however, a trend toward higher AF recurrences rates in patients ≥67 years was observed.</p> <p><strong>Conclusion: </strong>The data demonstrated a high degree of safety during CBA across all patient ages. Procedural performance and complications were similar between different ages; AF recurrences seem to be more frequent in patients over 74 years.</p>
Dataset related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation"
<p>This record contains raw data related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation" </p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p><strong>Aims: </strong>Pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) is mainly reserved for patients with drug-refractory or drug-intolerant symptomatic atrial fibrillation. We evaluated a large cohort of patients treated in a real-world setting and examined the safety and efficacy profile of CBA when applied as a first-line treatment for atrial fibrillation.</p> <p><strong>Methods: </strong>In total, 249 patients (23% women; 56 ± 13 years; mean left atrial diameter 41 ± 7 mm; 73.5% paroxysmal atrial fibrillation; and 26.5% persistent atrial fibrillation) underwent an index PVI by CBA. Data were collected prospectively in the framework of the 1STOP ClinicalService project, involving 26 Italian cardiology centers.</p> <p><strong>Results: </strong>Median procedure and fluoroscopy times were 90.0 and 21.0 min, respectively. Acute procedural success was 99.8%. Acute/periprocedural complications were observed in seven patients (2.8%), including: four transient diaphragmatic paralyses, one pericardial effusion (not requiring any intervention), one transient ischemic attack, and one minor vascular complication. The Kaplan--Meier freedom from atrial fibrillation recurrence was 86.3% at 12 months and 76% at 24 months. Seventeen patients (6.8%) had a repeat catheter ablation procedure during the follow-up period. At last follow-up, 10% of patients were on an anticoagulation therapy, whereas 6.8% were on an antiarrhythmic drug.</p> <p><strong>Conclusion: </strong>In our multicenter real-world experience, PVI by CBA in a first-line atrial fibrillation patient population was well tolerated, effective, and promising. CBA with a PVI strategy can be used to treat patients with paroxysmal and persistent atrial fibrillation with good acute procedural success, short procedure times, and acceptable safety.</p> <p><strong>Clinical trial registration: </strong>clinicaltrials.gov (<a href="http://clinicaltrials.gov/show/NCT01007474">NCT01007474</a>).</p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.